Common heart drug taken by millions found useless — and possibly dangerous

Researchers conducting a large international trial have challenged four decades of standard heart attack treatment, finding that beta blockers provide no protection for patients with normal heart function after uncomplicated heart attacks and may actively harm women taking them.

The study examined beta blockers, drugs routinely prescribed to millions of heart attack survivors globally to prevent future cardiac events. For patients whose hearts recovered normal function following their initial attack, the medications offered no survival benefit or reduction in repeat heart attacks, researchers determined.

The findings prove particularly troubling for women. Female patients receiving beta blockers experienced higher rates of death, recurrent heart attacks, and hospitalizations for heart failure compared to those not taking the drugs. Male patients showed no similar increased risk, suggesting sex-based differences in how the body metabolizes or responds to these medications.

Beta blockers work by slowing heart rate and reducing the force of cardiac contractions, theoretically protecting weakened hearts. Cardiologists adopted the practice after observing benefits in patients with severely damaged hearts. The assumption that benefits would extend to all post-heart attack patients, including those with normal recovery, went largely untested for decades.

This international trial enrolled sufficient patients to definitively establish that the traditional approach lacks evidence for this specific population. The research essentially asks physicians to reconsider a treatment pattern so entrenched that questioning it represents a significant departure from accepted practice.

The findings do not suggest that beta blockers lack value universally. Patients with reduced heart function, those with ongoing ischemia, or those with specific arrhythmias may still benefit from the medications. The distinction matters: not all heart attack survivors need identical post-event treatment.

The study's implications extend beyond individual prescribing decisions. Millions of people currently take beta blockers based on recommendations rooted in incomplete evidence. Healthcare systems worldwide may need to revise guidelines, potentially reducing unnecessary medication exposure and associated side effects. For women particularly,